• Consensus Rating: Buy
  • Consensus Price Target: $27.50
  • Forecasted Upside: 17.17%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$23.47
▼ -0.31 (-1.30%)

This chart shows the closing price for AORT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Artivion Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AORT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AORT

Analyst Price Target is $27.50
▲ +17.17% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Artivion in the last 3 months. The average price target is $27.50, with a high forecast of $30.00 and a low forecast of $25.00. The average price target represents a 17.17% upside from the last price of $23.47.

This chart shows the closing price for AORT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Artivion. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/5/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/5/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/3/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/1/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/30/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/28/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/28/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/28/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/7/2024Stifel NicolausBoost TargetBuy ➝ Buy$22.00 ➝ $25.00Low
5/7/2024Needham & Company LLCBoost TargetBuy ➝ Buy$25.00 ➝ $30.00Low
4/8/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$25.00Low
2/16/2024Stifel NicolausBoost TargetBuy ➝ Buy$20.00 ➝ $22.00Low
2/16/2024Needham & Company LLCBoost TargetBuy ➝ Buy$22.00 ➝ $25.00Low
12/7/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$22.00Low
11/3/2023Needham & Company LLCLower TargetBuy ➝ Buy$26.00 ➝ $22.00N/A
8/4/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$26.00Low
2/17/2023Needham & Company LLCReiterated RatingBuy$23.00N/A
11/4/2022Needham & Company LLCLower TargetBuy$28.00 ➝ $23.00Low
10/11/2022Morgan StanleyLower TargetEqual Weight$16.00 ➝ $14.00Low
9/27/2022Lake Street CapitalLower TargetBuy$32.00 ➝ $28.00Low
9/26/2022Morgan StanleyLower TargetEqual Weight$23.00 ➝ $16.00Low
9/26/2022OppenheimerLower TargetOutperform$35.00 ➝ $25.00Low
8/8/2022Lake Street CapitalInitiated CoverageBuy$32.00Low
7/15/2022Morgan StanleyLower TargetEqual Weight$23.00 ➝ $21.00Low
3/3/2022Stifel NicolausInitiated CoverageBuy$30.00Medium
2/18/2022Needham & Company LLCLower TargetBuy$39.00 ➝ $30.00High
(Data available from 5/28/2019 forward)

News Sentiment Rating

0.65 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/31/2023
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/30/2023
  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/30/2023
  • 4 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/29/2024
  • 4 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/28/2024
  • 11 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/29/2024
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/28/2024
  • 8 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/28/2024

Current Sentiment

  • 8 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Artivion logo
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.
Read More

Today's Range

Now: $23.47
Low: $23.34
High: $24.01

50 Day Range

MA: $21.67
Low: $19.62
High: $23.85

52 Week Range

Now: $23.47
Low: $12.16
High: $25.51

Volume

163,918 shs

Average Volume

213,016 shs

Market Capitalization

$978.70 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.66

Frequently Asked Questions

What sell-side analysts currently cover shares of Artivion?

The following Wall Street research analysts have issued reports on Artivion in the last year: Needham & Company LLC, and Stifel Nicolaus.
View the latest analyst ratings for AORT.

What is the current price target for Artivion?

2 Wall Street analysts have set twelve-month price targets for Artivion in the last year. Their average twelve-month price target is $27.50, suggesting a possible upside of 17.2%. Needham & Company LLC has the highest price target set, predicting AORT will reach $30.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $25.00 for Artivion in the next year.
View the latest price targets for AORT.

What is the current consensus analyst rating for Artivion?

Artivion currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AORT will outperform the market and that investors should add to their positions of Artivion.
View the latest ratings for AORT.

What other companies compete with Artivion?

How do I contact Artivion's investor relations team?

Artivion's physical mailing address is 1655 Roberts Blvd NW, Kennesaw, Georgia 30144-3632. The company's listed phone number is (770) 419-3355 and its investor relations email address is [email protected]. The official website for Artivion is www.cryolife.com. Learn More about contacing Artivion investor relations.